Related Experiment Video
Updated: Sep 20, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age
Fiona McLaughlin1, Paul Finn, Nicholas B La Thangue
1TopoTarget Prolifix, 87a Milton Park, Abingdon, Oxon, UK OX14 4RY.
Abstract:
Tumour cells grow and divide in an uncontrolled fashion. Recent advances in the cell cycle have uncovered new mechanisms that integrate growth and division with chromatin and gene expression control. Small-molecule drugs that target key enzyme classes involved in these pathways, the cyclin-dependent kinases (Cdk) in the cell cycle and histone deacetylases (HDAC) in chromatin control, have entered clinical studies, with emerging clinical efficacy. These new mechanism-based approaches could provide significant improvements over many current chemotherapeutics.
Insights
New cancer drugs targeting cell cycle kinases (Cdk) and chromatin deacetylases (HDAC) show promising clinical efficacy. These mechanism-based therapies offer potential improvements over traditional chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumour cells exhibit uncontrolled proliferation.
- Recent discoveries link cell cycle regulation with chromatin and gene expression.
- Existing chemotherapeutics have limitations.
Purpose of the Study:
- To explore novel therapeutic strategies for cancer.
- To investigate the role of Cdk and HDAC inhibitors in cancer treatment.
Main Methods:
- Review of recent advances in cell cycle and chromatin control research.
- Analysis of small-molecule drugs targeting cyclin-dependent kinases (Cdk) and histone deacetylases (HDAC).
- Examination of emerging clinical data on Cdk and HDAC inhibitors.
Main Results:
- Small-molecule inhibitors targeting Cdk and HDAC are in clinical studies.
- These targeted therapies demonstrate emerging clinical efficacy.
- Mechanism-based approaches integrate cell growth, division, and gene expression control.
Conclusions:
- Targeted inhibition of Cdk and HDAC represents a promising therapeutic avenue.
- These novel drugs may offer significant advantages over conventional chemotherapy.
- Further clinical development of Cdk and HDAC inhibitors is warranted.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
What is the Cell Cycle?
What is the Cell Cycle?
Mitogens and the Cell Cycle
Mitogens and the Cell Cycle

